Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
29 Avril 2024 - 1:00PM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first
quarter 2024 financial results on Thursday, May 2, 2024 after the
markets close. Management will conduct a conference call and live
webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the
financial results and to provide a business update.
Dial-in InformationU.S. Dial-in
Number: (888) 317-6003International Dial-in Number: (412)
317-6061Conference ID: 5993982
Replay InformationU.S. Dial-in
Number: (877) 344-7529Replay International Dial-in Number: (412)
317-0088Conference ID: 4019520
The dial-in replay will be available for 7 days
following the call. An audio webcast will be available online at
www.lexpharma.com/events, with a webcast replay accessible for 14
days after the call.
About Lexicon
Pharmaceuticals Lexicon is a biopharmaceutical
company with a mission of pioneering medicines that transform
patients’ lives. Through its Genome5000™ program, Lexicon
scientists studied the role and function of nearly 5,000 genes and
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. Lexicon is commercially launching one of these
medicines, INPEFA® (sotagliflozin) in the United States, and has a
pipeline of other promising drug candidates in discovery and
clinical and preclinical development in neuropathic pain, diabetes
and metabolism and other indications. For additional
information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s financial
position and long-term outlook on its business, growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that
are not historical facts or information. All forward-looking
statements are based on management’s current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including Lexicon’s ability to meet its
capital requirements, successfully commercialize INPEFA in heart
failure on the timeline and/or at the prices currently contemplated
or at all, conduct preclinical and clinical development and obtain
necessary regulatory approvals of INPEFA (in other indications),
LX9211 and its other drug candidates on its anticipated timelines,
achieve its operational objectives, obtain patent protection for
its discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates. Any of these risks, uncertainties and other factors may
cause Lexicon’s actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under “Risk Factors” in Lexicon’s annual report on Form
10-K for the year ended December 31, 2023 and other subsequent
disclosure documents filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or revise
any such forward-looking statements, whether as a result of new
information, future events or otherwise.
For Investor
Inquiries:
Lisa DeFrancesco Lexicon
Pharmaceuticals,
Inc. lexinvest@lexpharma.com
For Media Inquiries:
Alina Cocuzza Lexicon Pharmaceuticals,
Inc. acocuzza@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024